COMPANY

CorMedix

HQ: Parsippany, NJ source · cormedix.com ↗ · Mid-Atlantic

Location: Parsippany, NJ · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: Catheter-Related Infections Central Line Associated Blood Stream Infections Catheter-related Bloodstream Infection Chronic Kidney Failure Acute Kidney Injury Contrast-Induced Acute Kidney Injury deferiprone

$85.0MRaised (2 yrs)6Trials (company is sponsor)

Timeline

Jul 8, 2025 Trial start Phase 4: Open-Label Study to Assess Safety and Time to Catheter-related Bloodstream Infections (CRBSI) in Subjects From Birth to < 18 Years of Age source ↗
Jun 27, 2025 Raise Follow-on offering: $85M (total, as published), announced Jun 27, 2025. Source: SEC filing. source ↗
May 14, 2025 Trial start Phase 3: Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults And Adolescent Participants Receiving Total Parenteral Nutrition Through A source ↗
2015-12 Trial start Phase 3: Study Assessing Safety & Effectiveness of a Catheter Lock Solution in Dialysis Patients to Prevent Bloodstream Infection source ↗
2012-01 Trial start Phase 3: Efficacy and Safety of Deferiprone in Patients With Chronic Kidney Disease Undergoing a Cardiac Catheterization and Receiving Contrast Agent source ↗
2010-06 Trial start Phase 2: Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury source ↗

Upcoming milestones

2028-01 (ESTIMATED) · Phase 3 · Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults And Adolescent Participants Receiving Total Parenteral Nutrition Through A Central V · NCT06822426
2028-07 (ESTIMATED) · Phase 4 · Open-Label Study to Assess Safety and Time to Catheter-related Bloodstream Infections (CRBSI) in Subjects From Birth to < 18 Years of Age · NCT06714864

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $85.0M. Last 2 years.

Jun 27, 2025 Follow-on offering: $85M (total, as published), announced Jun 27, 2025. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 6

Record	Title	Phase	Status	Start	Primary completion
NCT06714864	Open-Label Study to Assess Safety and Time to Catheter-related Bloodstream Infections (CRBSI) in Subjects From Birth to < 18 Years of Age	Phase 4	Recruiting	Jul 8, 2025	2028-07 (estimated)
NCT06822426	Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults And Adolescent Participants Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)	Phase 3	Recruiting	May 14, 2025	2028-01 (estimated)
NCT06707480	Expanded Access Program for Patients at Risk for Catheter-related Infections Who Are Not Eligible for DefenCath® Clinical Trials	Not listed	No longer available	Not listed	Not listed
NCT02651428	Study Assessing Safety & Effectiveness of a Catheter Lock Solution in Dialysis Patients to Prevent Bloodstream Infection	Phase 3	Completed	2015-12	2018-10 (actual)
NCT01391520	Efficacy and Safety of Deferiprone in Patients With Chronic Kidney Disease Undergoing a Cardiac Catheterization and Receiving Contrast Agent	Phase 3	Withdrawn	2012-01	2013-03 (estimated)
NCT01146925	Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury	Phase 2	Completed	2010-06	2011-06 (actual)